GM Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$224K Sell
502
-25
-5% -$11.7K 0.01% 339
2025
Q4
$239K Buy
+527
New +$227K 0.01% 311
2025
Q3
Sell
-499
Closed -$222K 317
2025
Q2
$222K Sell
499
-14
-3% -$6.45K 0.01% 268
2025
Q1
$249K Hold
513
0.01% 235
2024
Q4
$207K Sell
513
-7
-1% -$3.25K 0.01% 247
2024
Q3
$242K Buy
520
+14
+3% +$6.72K 0.01% 221
2024
Q2
$237K Sell
506
-31
-6% -$13.5K 0.02% 205
2024
Q1
$224K Buy
+537
New +$227K 0.02% 207
2023
Q4
Sell
-799
Closed -$278K 209
2023
Q3
$278K Buy
+799
New +$279K 0.02% 163

Other funds holding VRTX

GM Advisory Group's VRTX Position: Q1 2026 in Review

GM Advisory Group reduced its Vertex Pharmaceuticals (VRTX) stake by 4.7% in Q1 2026, selling an estimated $11.7K and leaving 502 shares worth $224K. The position accounts for 0.01% of the portfolio, ranked #339.

GM Advisory Group first reported a position in VRTX in Q3 2023 and has held it in 9 quarters since. The position peaked at $278K in Q3 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • GM Advisory Group held 502 shares of Vertex Pharmaceuticals worth $224K as of Q1 2026.
  • GM Advisory Group sold 25 Vertex Pharmaceuticals shares in Q1 2026, an estimated $11.7K.
  • Vertex Pharmaceuticals made up 0.01% of GM Advisory Group's portfolio in Q1 2026, its #339 holding.
  • GM Advisory Group first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
  • GM Advisory Group's Vertex Pharmaceuticals position peaked at $278K in Q3 2023.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on GM Advisory Group's 13F filing for Q1 2026, filed 28 Apr 2026.